# US 2026/0015598 A1 · Compositions and methods for nucleic acid modifications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0015598 A1
- Document ID: US20260015598A1
- Status: Published application
- Kind: A1
- Application number: 18/873,215
- Filed: 2023-06-09
- Published: 2026-01-15
- Earliest claimed: 2022-06-10
- Assignees: Acrigen Biosciences
- Applicants: Acrigen Biosciences
- Inventors: David Rabuka; Michael Schelle; Allison Sharrar
- Web page: https://patentgrep.com/patent/US20260015598A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides nucleases and compositions, methods, and systems thereof for nucleic acid modification. More particularly, the present disclosure provides compositions and system comprising a nuclease comprising an amino acid sequence having at least 70% identity to any of SEQ ID NOs: 1-250 and at least one gRNA for target nucleic acid modification.

## Claims

### Claim 1

A composition comprising a nuclease, wherein the nuclease comprises a sequence with at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or with at least 99% identity to any one of SEQ ID NOs: 1-250.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amino acid sequence of the nuclease comprises any one of SEQ ID NOs: 1-250.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, wherein the nuclease further comprises a nuclear localization sequence (NLS) at the N-terminus, C-terminus, or both the N-terminus and C-terminus of the nuclease.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the NLS at the N-terminus and the NLS at the C-terminus of the nuclease are different sequences.

### Claim 5 (depends on 1, 2, 3, 4)

A nucleic acid comprising a first polynucleotide sequence encoding the nuclease of any of claims 1-4.

### Claim 6 (depends on 5)

A vector comprising the nucleic acid of claim 5.

### Claim 7 (depends on 6)

The vector of claim 6, further comprising a promoter operatively linked to the first polynucleotide.

### Claim 8 (depends on 6, 7)

The vector of claim 6 or 7, further comprising a second polynucleotide sequence encoding a guide RNA (gRNA).

### Claim 9 (depends on 8)

The vector of claim 8, further comprising a promoter operatively linked to the second polynucleotide sequence.

### Claim 10 (depends on 8, 9)

The vector of claim 8 or 9, wherein the gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NOs: 251-422 and 472-482.

### Claim 11 (depends on 8, 9, 10)

The vector of any of claims 8-10, wherein the gRNA comprises any one of SEQ ID NOs: 251-343.

### Claim 12 (depends on 8, 9, 10)

The vector of any of claims 8-10, wherein the gRNA comprises any one of SEQ ID NOs: 344-422.

### Claim 13 (depends on 8, 9, 10)

The vector of any of claims 8-10, wherein the gRNA comprises any one of SEQ ID NOs: 472-482.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

The vector of any one of claims 8-13, wherein the gRNA comprises a tracr sequence and the gRNA comprises one or more sequence deletions in or near the region encompassing the tracr sequence.

### Claim 15 (depends on 14)

The vector of claim 14, wherein the one or more sequence deletions comprises sequences predicted to form a stem-loop structure.

### Claim 16 (depends on 14, 15)

The vector of claim 14 or 15, wherein the one or more sequence deletions comprises sequences predicted to form a stem-loop structure at or near 5′ end of the gRNA.

### Claim 17 (depends on 14, 15, 16)

The vector of any of claims 14-16, wherein the gRNA comprises SEQ ID NO: 346.

### Claim 18 (depends on 14, 15, 16)

The vector of any of claims 14-16, wherein the gRNA comprises SEQ ID NO: 420.

### Claim 19 (depends on 14, 15, 16)

The vector of any of claims 14-16, wherein the gRNA comprises SEQ ID NO: 481.

### Claim 20 (depends on 14, 15, 16)

The vector of any of claims 14-16, wherein the gRNA comprises SEQ ID NO: 479.

### Claim 21 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The vector of any of claims 8-20, wherein the gRNA comprises a spacer sequence of at least 18 nucleotides in length or between 18 and 20 nucleotides in length.

### Claim 22

A system for modifying a target nucleic acid comprising:
a) a nuclease comprising an amino acid sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any of SEQ ID NOs: 1-250 or a nucleic acid encoding the nuclease; and
b) at least one guide RNA (gRNA) comprising a sequence complementary to at least a portion of a target nucleic acid and a region that associates with the nuclease, or a nucleic acid encoding the at least one gRNA.

### Claim 23 (depends on 22)

The system of claim 22, wherein the nuclease is capable of recognizing a protospacer adjacent motif (PAM) sequence selected from the group comprising ATTA, GTTA, ATTG, GTTG, TTTA, TTTG, CTTA, and CTTG.

### Claim 24 (depends on 22, 23)

The system of claim 22 or 23, wherein the gRNA comprises a spacer sequence complementary to a first strand sequence of the target nucleic acid, and wherein the first strand sequence is directly adjacent to a protospacer adjacent motif (PAM) sequence selected from the group comprising ATTA, GTTA, ATTG, GTTG, TTTA, TTTG, CTTA, and CTTG.

### Claim 25 (depends on 23, 24)

The system of claim 23 or 24, wherein the PAM sequence comprises DTTR, wherein D is A, G, or T and R is A or G.

### Claim 26 (depends on 22, 23, 24, 25)

The system of any one of claims 22-25, wherein the nuclease is capable of preferentially modifying a target nucleic acid comprising PAM sequence ATTA as compared to a target nucleic acid comprising PAM sequence TTTR, wherein R is A or G.

### Claim 27 (depends on 22, 23, 24, 25)

The system of any one of claims 22-25, wherein the nuclease is capable of a higher efficiency of modification of the target nucleic acid as compared to the efficiency of modification of the target nucleic acid by nuclease SEQ ID NO: 471, wherein the target nucleic acid comprises PAM sequence is ATTA.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

The system of any of claims 22-27, wherein modifying comprises nucleic acid cleavage.

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The system of any of claims 22-28, wherein modifying comprises one or more of modification of the target nucleic acid, modulation of transcription from the target nucleic acid, and modification of a polypeptide associated with a target nucleic acid.

### Claim 30 (depends on 22, 23, 24, 25, 26, 27, 28, 29)

The system of any of claims 22-29, wherein the nuclease further comprises a nuclear localization sequence (NLS) at the N-terminus, C-terminus, or both the N-terminus and C-terminus of the nuclease.

### Claim 31 (depends on 30)

The system of claim 30, wherein the NLS at the N-terminus and the NLS at the C-terminus of the nuclease are different sequences.

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The system of any of claims 22-31, wherein the nuclease further comprises a purification tag.

### Claim 33 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The system of any of claims 22-32, wherein the at least one gRNA further comprises a sequence complementary to at least a portion of a second target nucleic acid.

### Claim 34 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The system of any of claims 22-33, wherein the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 251-422.

### Claim 35 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises any one of SEQ ID NOs: 251-343.

### Claim 36 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises any one of SEQ ID NOs: 344-422.

### Claim 37 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises any one of SEQ ID NOs: 472-482.

### Claim 38 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises SEQ ID NO: 346.

### Claim 39 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises SEQ ID NO: 420.

### Claim 40 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises SEQ ID NO: 481.

### Claim 41 (depends on 34)

The system of claim 34, wherein the at least one gRNA comprises SEQ ID NO: 479.

### Claim 42 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The system of any of claims 22-41, wherein the at least one gRNA comprises a spacer sequence of at least 18 nucleotides in length or between 18 and 20 nucleotides in length.

### Claim 43 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 20, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 309, 346, 352, 358, 362-364, 380, 392-395, 410-420, 472-479, and 481, or any one of SEQ ID NOs: 352, 358, 363, 364, 380, 392, and 417, or any one of SEQ ID NOs: 346 and 362, or any one of SEQ ID NOs: 410-419.

### Claim 44 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The system of any of claims 22-43, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 20, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 309, 346, 352, 358, 362-364, 380, 392-395, 410-420, 472-479, and 481 or any one of SEQ ID NOs: 352, 358, 363, 364, 380, 392, and 417, or any one of SEQ ID NOs: 346 and 362, or any one of SEQ ID NOs: 410-419.

### Claim 45 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 21, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 310, 344-349, 361-366, 404-422, and 479-482.

### Claim 46 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 310, 344-349, 361-366, 404-422, and 479-482.

### Claim 47 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 22, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 311, 346, 381, and 398-399.

### Claim 48 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 22, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 311, 346, 381, and 398-399.

### Claim 49 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 23, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 312, 346, and 382.

### Claim 50 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 23, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 312, 346, and 382.

### Claim 51 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 24, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 310, 313, 325, 346, 350-355, 358, 361-363, 367-372, and 389-392, or any one of SEQ ID NOs: 346, 352, 358, 361, 362, 368, 369, and 392.

### Claim 52 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 24, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 310, 313, 325, 346, 350-355, 358, 361-363, 367-372, and 389-392, or any one of SEQ ID NOs: 346, 352, 358, 361, 362, 368, 369, and 392.

### Claim 53 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 25, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 314, 346, 383, and 400.

### Claim 54 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 25, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 314, 346, 383, and 400.

### Claim 55 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 26, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 315, 346, 384, 392, 396-397, 420, 479, and 481, or any one of SEQ ID NOs: 346, 384 and 392.

### Claim 56 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 26, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 315, 346, 384, 392, 396-397, 420, 479, and 481, or any one of SEQ ID NOs: 346, 384 and 392.

### Claim 57 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 27, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 316, 346, 385, and 401.

### Claim 58 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 27, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 316, 346, 385, and 401.

### Claim 59 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 28, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 317, 346, 386, and 402.

### Claim 60 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 28, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 317, 346, 386, and 402.

### Claim 61 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 29, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 318, 346, 387, and 403.

### Claim 62 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 318, 346, 387, and 403.

### Claim 63 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises SEQ ID NO: 36, and the at least one gRNA comprises a sequence with at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to any one of SEQ ID NOs: 310, 313, 325, 346, 356-360, and 373-378.

### Claim 64 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The system of any of claims 22-42, wherein the nuclease comprises a sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 36, and wherein the at least one gRNA comprises any one of SEQ ID NOs: 310, 313, 325, 346, 356-360, and 373-378.

### Claim 65 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The system of any of claims 22-64, wherein the nucleic acid molecule encoding each one or both of the nuclease and the at least one gRNA comprises a messenger RNA, a vector, or a combination thereof.

### Claim 66 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The system of any of claims 22-65, wherein the nuclease and the at least one gRNA are encoded on one nucleic acid.

### Claim 67 (depends on 66)

The system of claim 66, wherein the nuclease and the at least one gRNA are operatively linked to different promoters.

### Claim 68 (depends on 66, 67)

The system of claim 66 or 67, wherein the one nucleic acid is a vector.

### Claim 69 (depends on 68)

The system of claim 68, wherein the vector is a viral vector.

### Claim 70 (depends on 69)

The system of claim 69, wherein the viral vector is an AAV vector.

### Claim 71 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A kit comprising the system of any one of claims 22-70.

### Claim 72 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A cell comprising the system of any one of claims 22-70.

### Claim 73 (depends on 72)

The cell of claim 72, wherein the cell is a prokaryotic or eukaryotic cell.

### Claim 74 (depends on 72, 73)

The cell of claim 72 or 73, wherein the cell is a mammalian cell.

### Claim 75 (depends on 72, 73, 74)

The cell of any of claims 72-74, wherein the cell is a human cell.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A method of modifying a selected target nucleic acid sequence comprising contacting the selected target nucleic acid with a composition of any one of claims 1-4, a nucleic acid of claim 5, a vector of any one of claims 6-21, or a system of any one of claims 22-70.

### Claim 77 (depends on 76)

The method of claim 76, wherein the target nucleic acid sequence is in a cell.

### Claim 78 (depends on 77)

The method of claim 77, wherein the cell is a prokaryotic or eukaryotic cell.

### Claim 79 (depends on 77, 78)

The method of claim 77 or 78, wherein the cell is a mammalian cell.

### Claim 80 (depends on 76, 77, 78)

The method of any of claims 76-78, wherein the cell is a human cell.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 76, 77, 78, 79, 80)

The method of any of claims 76-80, wherein the contacting comprises introducing the composition of any one of claims 1-4, the nucleic acid of claim 5, the vector of any one of claims 6-21, or the system of any one of claims 22-69 into the cell.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 76, 77, 78, 79, 80)

The method of any of claims 75-80, wherein the contacting comprises administering introducing the composition of any one of claims 1-4, the nucleic acid of claim 5, the vector of any one of claims 6-21, or the system of any one of claims 22-70 to a subject.

### Claim 83 (depends on 76, 77, 78, 79, 80, 81, 82)

The method of any of claims 76-82, wherein the selected target nucleic acid sequence encodes a gene product.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A composition of any one of claims 1-4, a nucleic acid of claim 5, a vector of any one of claims 6-21, or a system of any one of claims 22-70 for use in modifying a selected target nucleic acid sequence.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A kit comprising composition of any one of claims 1-4, a nucleic acid of claim 5, a vector of any one of claims 6-21, or a system of any one of claims 22-70 for use in modifying a selected target nucleic acid sequence in an in vitro assay.
